The rates of HER3+ were 30.3 - 75.1% in breast cancers, 51.1 - 74.5% in colorectal cancers, 13.7 - 59.0% in gastric cancers, 54.5 - 74.4% in cervical carcinomas, 53.3% in melanomas, and 9.0% in head and neck squamous cell carcinomas (Figure 2). This evidence concerns the gene ERBB3 and colorectal cancer.